Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5392-5398

  Poulaki, Vassiliki ^a   Mitsiades, Constantine S ^a   McMullan, Ciaran ^a   Sykoutri, Despoina ^a   Fanourakis, Galinos ^a   Kotoula, Vassiliki ^b   Tseleni Balafouta, Sophia ^c   Koutras, Demetrios A ^c   Mitsiades, Nicholas ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Evgenidion Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTISENSE OLIGONUCLEOTIDE; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; WORTMANNIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THYROID CARCINOMA; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; BENZOQUINONES; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR I; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LACTAMS, MACROCYCLIC; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINONES; RECEPTOR, IGF TYPE 1; THYROID NEOPLASMS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0344874254     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030389     Document Type: Article

References (36)

1. Folkman J 2000 Tumor angiogenesis. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, Gansler TS, eds. Cancer medicine. Hamilton, ON: B. C. Decker Inc.; 132-152
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985
3. Ferrara N, Houck K, Jakeman L, Leung DW 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32
4. Salnikow K, Kluz T, Costa M, Piquemal D, Demidenko ZN, Xie K, Blagosklonny MV 2002 The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol 22:1734-1741
5. Damert A, Ikeda E, Risau W 1997 Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 327:419-423
6. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP 2002 Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 160:501-509
7. Folkman J 1995 Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763
8. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, Kakinuma S, Oosuga I, Wada S, Katayama S 1998 Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 83:3908-3912
9. Toda S, Nishimura T, Yamada S, Koike N, Yonemitsu N, Watanabe K, Matsumura S, Gartner R, Sugihara H 1999 Immunohistochemical expression of growth factors in subacute thyroiditis and their effects on thyroid folliculogenesis and angiogenesis in collagen gel matrix culture. J Pathol 188:415-422
10. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A, Leclere J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41-49
11. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M 1995 Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96:1295-1302
12. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747
13. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976
14. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742
15. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, et al 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579
16. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY 2000 Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128:1059-1066
17. Xu G, Pan J, Martin C, Yeung SC 2001 Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769-1777
18. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658
19. Gonsky R, Knauf JA, Elisei R, Wang JW, Su S, Fagin JA 1997 Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. Nucleic Acids Res 25:3823-3831
20. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC 2001 TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795-804
21. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP 2002 Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF. J Clin Invest 109:805-815
22. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC 2002 Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21:5673-5683
23. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525-4530
24. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC 2002 Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
25. Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N 2002 Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 161:643-654
26. Basso AD, Solit DB, Munster PN, Rosen N 2002 Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-1166
27. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N 2002 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/ neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
28. Akeno N, Robins J, Zhang M, Czyzyk-Krzeska MF, Clemens TL 2002 Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2α. Endocrinology 143:420-425
29. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A 2001 The IGF system in thyroid cancer: new concepts. Mol Pathol 54:121-124
30. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD 2001 Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11:339-351
31. Mitsiades CS, Poulaki V, Mitsiades N 2001 Insulin-like growth factor (IGF)-1 protects thyroid carcinoma cells from TRAIL-induced apoptosis. Proc Am Assoc Cancer Res 42:272
32. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA, Tsokos M 1999 Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab 84:2924-2932
33. Chambers AF, Matrisian LM 1997 Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270
34. Sato K 2001 Vascular endothelial growth factors and thyroid disorders. Endocr J 48:635-646
35. Dunn FB 2002 Heat shock protein inhibitor shows antitumor activity. J Natl Cancer Inst 94:1194-1195
36. Munster PN, Srethapakdi M, Moasser MM, Rosen N 2001 Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 61:2945-2952